Part I
Articles by LPBI Group’s Team Member
Adipocyte Derived Stroma Cells: Their Usage in Regenerative Medicine and Reprogramming into Pancreatic Beta-Like Cells
Curator: Evelina Cohn, PhD
Fat Cells Reprogrammed to Make Insulin
Curator: Larry H. Bernstein, MD, FCAP
Part II
Diabetes: All Drugs in Development
Curator: Stephen J Williams, PhD
| Table 1. Drugs in Development1–3 | |||
| Generic/Code Name | Manufacturer | Indication | Phase |
| DPP-4 Inhibitors | |||
| Alogliptin/SYR-322 | Takeda | Type 2 diabetes | NDA submitted |
| AMG 222/ALS2- 0426 | Amgen/Servier | Type 2 diabetes | 2 |
| Dutogliptin/PHX1149 | Phenomix/Forest Laboratories | Type 2 diabetes | 3 |
| KRP-204/N-5984 | Kyorin | Type 2 diabetes | 2 |
| KRP-104 | Kyorin/ActivX Biosciences | Type 2 diabetes | 2 |
| Linagliptin/BI-1356 | Boehringer Ingelheim | Type 2 diabetes | 3 |
| Melogliptin/GRC 8200 | Glenmark Pharmaceuticals | Type 2 diabetes | 2 |
| MP-513 | Mitsubishi Tanabe Pharma | Type 2 diabetes | 2 |
| PF 734200 | Pfizer | Type 2 diabetes | 2 |
| R1579 | Roche/Chugai | Type 2 diabetes | 2 |
| Saxagliptin/BMS-477118 | Bristol-Myers Squibb/AstraZeneca | Type 2 diabetes | NDA submitted |
| SYR 472 | Takeda | Type 2 diabetes | 2 |
| TA-6666 | Mitsubishi Tanabe | Type 2 diabetes | 2 |
| Vildagliptin | Novartis | Type 2 diabetes | NDA submitted |
| GLP-1 Analogs | |||
| Albiglutide/GSK716155 | GSK | Type 2 diabetes | 2 |
| AVE0010/ZP-10 | Sanofi-Aventis | Type 2 diabetes | 3 |
| CJC-1134-PC/PC-DAC: Exendin-4 | ConjuChem | Type 2 diabetes | 2 |
| Exenatide LAR | Amylin/Alkermes/Lilly | Type 2 diabetes | 3 |
| Liraglutide/NN2211 | Novo Nordisk | Type 2 diabetes | NDA submitted |
| LY 2189265 | Lilly | Type 2 diabetes | 3 |
| NN9535 | Novo Nordisk | Type 2 diabetes | 2 |
| Taspoglutide/R1583/BIM-51077 | Roche/Ipsen | Type 2 diabetes | 3 |
| Biguanides | |||
| Metformin gum/buccal | Generex/Fertin Pharma | Type 2 diabetes | 2 |
| Thiazolidinediones/PPAR-γ Agonists | |||
| Balaglitazone/DRF-2593 | Dr. Reddy’s Laboratories/Rheoscience | Type 2 diabetes | 3 |
| Mitoglitazone/MDSC 0160 | Metabolic Solutions Development | Type 2 diabetes | 2 |
| Netoglitazone/MCC-55 | Mitsubishi Tanabe/Perlegen | Type 2 diabetes | 2 |
| Rivoglitazone/CS-011 | Daiichi-Sankyo | Type 2 diabetes | 3 |
| Other PPAR Agonists | |||
| Aleglitazar/R1439 | Roche | Type 2 diabetes | 2 |
| Indeglitazar | Pexxikon/Wyeth | Type 2 diabetes | 2 |
| INT 131/AMG131 | Amgen/InteKrin Therapeutics | Type 2 diabetes | 2 |
| MBX 2044 | Metabolex/Ortho-McNeil | Type 2 diabetes | 2 |
| Metaglidasen/MBX 102/JNJ-39659100 | Metabolex/Ortho-McNeil | Type 2 diabetes | 2 |
| ONO-5129 | Ono | Type 2 diabetes | 2 |
| PLX204/PPM-204 | Plexxikon/Wyeth | Type 2 diabetes | 2 |
| Selective Sodium Glucose Cotransporter Inhibitors | |||
| ASP1941 | Astellas | Type 2 diabetes | 2 |
| AVE2268 | Sanofi-Aventis | Type 2 diabetes | 2 |
| BI 10773 | Boehringer Ingelheim | Type 2 diabetes | 2 |
| Dapagliflozin/BMS512148 | AstraZeneca/Bristol-Myers Squibb | Type 2 diabetes | 3 |
| KGT-1681 | GSK/Kissei | Type 2 diabetes | 2 |
| Remogliflozin/189075 | GSK/Kissei | Type 2 diabetes | 2 |
| TA-7284 | Mitsubishi Tanabe/Ortho McNeil | Type 2 diabetes | 2 |
| YM543 | Astellas | Type 2 diabetes | 2 |
| Glinides | |||
| Mitiglinide | Elixir Pharmaceuticals | Type 2 diabetes | 3 |
| Insulins | |||
| Inhaled Technosphere insulin | Mannkind | Type 1 and type 2 diabetes | 3 |
| Insulin intranasal | Bentley | Type 1 and type 2 diabetes | 2 |
| Insulin intranasal | MDRNA | Type 2 diabetes | 2 |
| Oral HDV insulin | Diasome | Type 2 diabetes | 2 |
| Oral insulin spray | Generex | Type 1 and type 2 diabetes | 3 |
| NN1250 insulin analog for injection |
Novo Nordisk | Type 1 and type 2 diabetes | 2 |
| NN5401 insulin analog for injection |
Novo Nordisk | Type 1 and type 2 diabetes | 2 |
| Rapid-acting insulin for injection | Biodel | Type 1 and type 2 diabetes | 3 |
| Recombinant human hyaluroindase (rHuPH20)/insulin co-formulation for injection | Halozyme Therapeutics | Type 1 diabetes | 2 |
| Other Drugs in Development | |||
| Generic/Code Name | Manufacturer | Mechanism | Indication |
| AJD101 | Daiichi Sankyo | Activates insulin signaling pathway | Type 2 diabetes |
| AKP- 020 | Akesis | Vanadium compound | Type 2 diabetes |
| AMG-108 | Amgen | Interleukin-1 inhibitor | Type 2 diabetes |
| AZD6370 | AstraZeneca | Glucokinase activator | Type 2 diabetes |
| Bromocriptine | VeroScience | Dopamine D2 receptor agonist |
Type 2 diabetes |
| Canakinumab/ACZ885 | Novartis | Anti-interleukin-1 beta antibody | Type 2 diabetes |
| Colestimide | Mitsubishi-Tanabe | Unknown | Type 2 diabetes |
| Bezafibrate + diflunisal/ CRx-401 | CombinatoRx | Unknown | Type 2 diabetes |
| DIO-902/2S,4R ketoconazole | DiObex | Cortisol synthesis inhibitor | Type 2 diabetes |
| DM-71/bethanechol and N-acetyl cysteine | Diamedica | Unknown | Type 2 diabetes |
| DM-83/combination of two generic compounds | Diamedica | Unknown | Type 2 diabetes |
| E1 INT | Transition Therapeutics | Islet regeneration factor | Type 1 and type 2 diabetes |
| Eprodisate/NC-503 | Bellus Health | Serum amyloid A protein inhibitor | ? |
| Ex vivo cultured adult human mesenchymal stem cells | Osiris | Mesenchymal stem cell therapy |
Type 1 diabetes |
| HE3286 | Hollis-Eden | Insulin sensitizer (NF-kappaB pathway/TLR4 receptor) | Type 2 diabetes |
| INCB 13739 | Incyte | 11-beta hydroxysteroid dehydrogenase inhibitor | Type 2 diabetes |
| INCB 19602 | Incyte | GPR109A receptor agonist / HM74a agonist | Type 2 diabetes |
| INGAP peptide | Kinexum | Islet neogenesis associated protein | Type 1 and type 2 diabetes |
| ISIS 113715 | Isis | PTP1B | Type 2 diabetes |
| MB 07803 | Metabasis/Daiichi Sankyo |
Fructose-1,6-bisphosphatase inhibitor | Type 2 diabetes |
| MK 0893 | Merck | Unknown | Type 2 diabetes |
| MK 0941 | Merck | Unknown | Type 2 diabetes |
| Otelixizumab/TRX4 | GSK, Tolerx | Anti-CD3 MAb | Type 1 diabetes |
| rhGAD65/recombinant human glutamic acid decarboxylase | Diamyd Therapeutics | Vaccine/induces immunmotolerization | Type 1 diabetes |
| Succinobucol/AGI 1067 | AtheroGenics | Antioxidant/vascular cell adhesion molecule-1 | Type 2 diabetes |
| Tagatose | Spherix | Attenuates intestinal glucose absorption | Type 2 diabetes |
| Teplizumab/MGA031/ hOKT3gamma1(Ala-Ala) | Lilly/MacroGenics | Anti-CD3 MAb | Type 1 diabetes |
| TT-223 | Lilly/Transition Therapeutics | Gastrin analog | Type 1 and type 2 diabetes |
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Daniel Menzin
Dror Nir
dsmolyar
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
pkandala
Rosalind Codrington, PhD
ritusaxena
Rick Mandahl
sjwilliamspa
stuartlpbi
Dr. Sudipta Saha
tildabarliya
zraviv06
zs22